TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded TriSalus Life Sciences from “Sell” to “Hold.” MarketBeat’s analyst consensus is also “Hold,” with an average price target of $7.50.
• TriSalus reported quarterly revenue of $11.41 million, exceeding expectations of $10.27 million, while adjusted EPS of negative $0.16 matched consensus estimates.
• The stock opened at $5.27, with a market capitalization of approximately $324.5 million and a 52-week range of $2.20 to $7.95. Institutional investors own 2.58% of the shares.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday.

Other research analysts have also recently issued reports about the company. Lake Street Capital dropped their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.50.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $5.27 on Friday. The company has a market cap of $324.53 million, a PE ratio of -4.05 and a beta of 0.43. The business has a 50 day moving average of $4.58 and a 200 day moving average of $4.32. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The company had revenue of $11.41 million during the quarter, compared to analysts' expectations of $10.27 million.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences during the 1st quarter worth approximately $20,267,000. Perkins Capital Management Inc. bought a new position in shares of TriSalus Life Sciences during the 1st quarter valued at approximately $920,000. Wasatch Advisors LP purchased a new position in shares of TriSalus Life Sciences in the first quarter valued at $5,752,000. Empire Financial Management Company LLC grew its holdings in shares of TriSalus Life Sciences by 316.9% in the first quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company's stock valued at $1,201,000 after purchasing an additional 228,248 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its position in TriSalus Life Sciences by 16.0% in the second quarter. Bridgeway Capital Management LLC now owns 75,400 shares of the company's stock worth $411,000 after purchasing an additional 10,400 shares during the last quarter. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source